Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - ashpublications.org
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …
被引用次数：28 相关文章
[HTML] sciencedirect.com

[HTML][HTML] Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, HT Kim, HM Murdock, CS Cutler, J Brock… - Blood Advances, 2021 - Elsevier
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.

JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - europepmc.org
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - pubmed.ncbi.nlm.nih.gov
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …
[PDF] semanticscholar.org

[PDF][PDF] Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, HT Kim, HM Murdock, CS Cutler, J Brock… - pdfs.semanticscholar.org
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …

[引用][C] Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, CS Cutler, J Brock, M Gooptu, VT Ho… - Blood Advances, 2021 - elibrary.ru
Research reported in this publication was supported by the Ted and Eileen Pasquarello
Tissue Bank in Hematologic Malignancies and the National Cancer Institute (NCI) of the …
[HTML] nih.gov

[HTML][HTML] Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - ncbi.nlm.nih.gov
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.

JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - europepmc.org
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …